Search results for: 'security screening systems xaas global'

Organ-on-a-chip technology involves the incorporation of microphysiological systems harboring dynamic living 3D organoids, tissue-culture, or cell cultures on a microfluidic platform. The physiologically relevant Organ-chip models offer a better and more precise insight to the possible in vivo effects of drugs in the human body. The flexibility of ...

25 Jul 2018  |  North America  |  Market Research

Global X-ray Mammography Imaging Systems Market, Forecast to 2022

Evaluating Growth Patterns and Opportunities Across X-ray Mammography Sets

Infographics

×

Over the last 20 years, hospitals and imaging centers in developed economies have adopted X-ray mammography equipment to screen and diagnose breast cancer. This has led to significant reduction in mortality and prompted emerging countries to invest in population-based, organized screening. Significant investments in mammography technology have pave...

Liquid biopsy (CTCs and ctDNAs) is slowly gaining momentum in clinical care given its advantages over the traditional tissue-based gold standard methods. Short-term applications in cancer care range from risk assessment to cancer recurrence monitoring. Despite the proven advantages, there is still a significant number of barriers to adoption such a...

21 Jun 2018  |  North America  |  Market Research

Endoscope Reprocessing Systems and Software Solutions Market Assessment, United States, Forecast to 2022

Despite Reaching Near Saturation, the Market will Grow at Healthy Rate Driven by High Procedural Volume Growth Coupled with Consistently High Replacements and Newer Installations

Infographics

×

Endoscope reprocessing systems and workflow solutions was a $526.6 million market in the United States in 2017. It is expected to grow at healthy CAGR of 8.6% to reach $796.4 million in 2022. The market is segmented into two broad segments which are then divided into several sub-segments as mentioned below: • Endoscope reprocessing solutions ...

03 Jan 2018  |  North America  |  Market Outlook

Global Healthcare Industry Outlook, 2018

Value-based Care Will Continue to Drive Growth Opportunities for Emerging Technologies as They Move Out form Pilot Testing into Production Environments

Infographics

×

Key Issues Addressed Key Benefits

In this research deliverable, Frost & Sullivan provides bold perspectives and predictions for the global healthcare industry in 2018. The markets covered include pharmaceuticals and biotech, in-vitro diagnostics, medical technologies, medical imaging, and healthcare IT. The analysis captures sectoral and regional trends and provides predictions for...

The market for endoscope reprocessing systems and workflow solutions in Australia was worth A$61.1 million in 2017. It is expected to grow at a robust CAGR of 10.1% to reach a market size of A$98.7 million in 2022. The market is segmented into two broad segments, which are then divided into several sub-segments as mentioned below – • Endoscope r...

Endoscope reprocessing systems and workflow solutions was a €416.4 million market in the top five Western European countries (UK, Germany, France, Spain, and Italy) in 2017. It is expected to grow at a robust CAGR of 9.5% to reach a revenue of €654.9 million by 2022. The market is segmented into two broad segments which are then divided into severa...

The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from ...

24 Oct 2018  |  North America  |  Market Research

Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025

A Robust Product Pipeline Creating Opportunities for Ground-breaking Combination Therapies is Set to Revolutionize the Global Cell Therapy Market

Infographics

×

Key Issues Addressed

The global pharmaceuticals industry is continuously evolving to meet the requirements of a changing disease landscape. With the increasing prevalence of chronic infectious diseases and cancer, market needs are shifting from traditional small molecules to novel large molecule therapies, with cell therapies dominating the space. This study presents a...